[HTML][HTML] Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis
R Wolk, EJ Armstrong, PR Hansen, B Thiers… - Journal of clinical …, 2017 - Elsevier
Background Psoriasis is a systemic inflammatory disease associated with increased
cardiovascular (CV) risk and altered lipid metabolism. Tofacitinib is an oral Janus kinase
inhibitor. Objective The aim of the study was to investigate the effects of tofacitinib on
traditional and nontraditional lipid parameters and CV risk markers in patients with psoriasis
from a phase III study, OPT Pivotal 1. Methods Patients with psoriasis were randomized to
tofacitinib 5 or 10 mg twice daily (BID) or placebo BID. Serum samples were collected at …
cardiovascular (CV) risk and altered lipid metabolism. Tofacitinib is an oral Janus kinase
inhibitor. Objective The aim of the study was to investigate the effects of tofacitinib on
traditional and nontraditional lipid parameters and CV risk markers in patients with psoriasis
from a phase III study, OPT Pivotal 1. Methods Patients with psoriasis were randomized to
tofacitinib 5 or 10 mg twice daily (BID) or placebo BID. Serum samples were collected at …